Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 685213, 9 pages
http://dx.doi.org/10.1155/2012/685213
Review Article

Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics

Pathophysiology Section, Department of Experimental Medicine, Sapienza University of Rome, Viale del Policlinico, 155-00161 Rome, Italy

Received 27 April 2012; Accepted 13 June 2012

Academic Editor: Marialuisa Appetecchia

Copyright © 2012 Carlotta Pozza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. S. Woo, A. M. Isidori, W. Z. Wat et al., “Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4963–4969, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. M. Bush, J. A. Longtine, T. Cunningham et al., “Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. E280–E290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. Isidori, G. A. Kaltsas, C. Pozza et al., “The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 371–377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. B. M. K. Biller, A. B. Grossman, P. M. Stewart et al., “Treatment of adrenocorticotropin-dependent cushing's syndrome: a consensus statement,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2454–2462, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Arnaldi, A. Angeli, A. B. Atkinson et al., “Diagnosis and complications of Cushing's syndrome: a consensus statement,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 12, pp. 5593–5602, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Assié, H. Bahurel, J. Bertherat, M. Kujas, P. Legmann, and X. Bertagna, “The Nelson's syndrome... revisited,” Pituitary, vol. 7, no. 4, pp. 209–215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. T. M. Barber, E. Adams, O. Ansorge, J. V. Byrne, N. Karavitaki, and J. A. H. Wass, “Nelson's syndrome,” European Journal of Endocrinology, vol. 163, no. 4, pp. 495–507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Jenkins, P. J. Trainer, P. N. Plowman et al., “The long term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 1, pp. 165–171, 1995. View at Google Scholar · View at Scopus
  9. A. P. Heaney, “PPAR-γ in Cushing's disease,” Pituitary, vol. 7, no. 4, pp. 265–269, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Newell-Price, X. Bertagna, A. B. Grossman, and L. K. Nieman, “Cushing's syndrome,” Lancet, vol. 367, no. 9522, pp. 1605–1617, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Deuschle, O. Lecei, G. K. Stalla et al., “Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus-pituitary-adrenal system in healthy humans,” Neuropsychopharmacology, vol. 28, no. 2, pp. 379–383, 2003. View at Google Scholar · View at Scopus
  12. L. Jimenez Reina, A. Leal-Cerro, J. Garcia, P. P. Garcia-Luna, R. Astorga, and G. Bernal, “In vitro effects of ketoconazole on corticotrope cell morphology and ACTH secretion of two pituitary adnomas removed from patients with Nelson's syndrome,” Acta Endocrinologica, vol. 121, no. 2, pp. 185–190, 1989. View at Google Scholar · View at Scopus
  13. G. K. Stalla, J. Stalla, K. Von Werder et al., “Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme,” Endocrinology, vol. 125, no. 2, pp. 699–706, 1989. View at Google Scholar · View at Scopus
  14. D. Engelhardt and M. M. Weber, “Therapy of Cushing's syndrome with steroid biosynthesis inhibitors,” Journal of Steroid Biochemistry and Molecular Biology, vol. 49, no. 4–6, pp. 261–267, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Thoren, U. Adamson, and H. E. Sjoberg, “Aminoglutethimide and metyrapone in the management of Cushing's syndrome,” Acta Endocrinologica, vol. 109, no. 4, pp. 451–457, 1985. View at Google Scholar · View at Scopus
  16. J. A. Verhelst, P. J. Trainer, T. A. Howlett et al., “Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome,” Clinical Endocrinology, vol. 35, no. 2, pp. 169–178, 1991. View at Google Scholar · View at Scopus
  17. D. A. Calhoun, W. B. White, H. Krum et al., “Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial,” Circulation, vol. 124, pp. 1945–1955, 2011. View at Google Scholar
  18. M. Terzolo, A. Angeli, M. Fassnacht et al., “Adjuvant mitotane treatment for adrenocortical carcinoma,” New England Journal of Medicine, vol. 356, no. 23, pp. 2372–2380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Leiba, R. Weinstein, B. Shindel et al., “The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo,” Annales d'Endocrinologie, vol. 50, no. 1, pp. 49–53, 1989. View at Google Scholar · View at Scopus
  20. J. P. Luton, J. A. Mahoudeau, P. Bouchard et al., “Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases,” New England Journal of Medicine, vol. 300, no. 9, pp. 459–464, 1979. View at Google Scholar · View at Scopus
  21. A. P. Van Seters and A. J. Moolenaar, “Mitotane increases the blood levels of hormone-binding proteins,” Acta Endocrinologica, vol. 124, no. 5, pp. 526–533, 1991. View at Google Scholar · View at Scopus
  22. N. Nader, G. Raverot, A. Emptoz-Bonneton et al., “Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2165–2170, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. V. A. Preda, J. Sen, N. Karavitaki, and A. Grossman, “THERAPY IN ENDOCRINE DISEASE: Etomidate in the management of hypercortisolaemia in Cushing's syndrome,” European Journal of Endocrinology, vol. 167, no. 2, pp. 137–143, 2012. View at Google Scholar
  24. W. M. Drake, L. A. Perry, C. J. Hinds, D. G. Lowe, R. H. Reznek, and G. M. Besser, “Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 10, pp. 3542–3544, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Krakoff, C. A. Koch, K. A. Calis, R. H. Alexander, and L. K. Nieman, “Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 9, pp. 4104–4108, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. N. A. Tritos and B. M. Biller, “Advances in medical therapies for Cushing's syndrome,” Discovery Medicine, vol. 13, pp. 171–179, 2012. View at Google Scholar
  27. F. Castinetti, M. Fassnacht, S. Johanssen et al., “Merits and pitfalls of mifepristone in Cushing's syndrome,” European Journal of Endocrinology, vol. 160, no. 6, pp. 1003–1010, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Castinetti, B. Conte-Devolx, and T. Brue, “Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone,” Neuroendocrinology, vol. 92, no. 1, supplement, pp. 125–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. S. S. Praw and A. P. Heaney, “Medical treatment of Cushing's disease: overview and recent findings,” International Journal of General Medicine, vol. 2, pp. 209–217, 2009. View at Google Scholar · View at Scopus
  30. P. Petrossians, A. S. Thonnard, and A. Beckers, “Medical treatment in Cushing's syndrome: dopamine agonists and cabergoline,” Neuroendocrinology, vol. 92, no. 1, pp. 116–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Pivonello, D. Ferone, W. W. De Herder et al., “Dopamine receptor expression and function in corticotroph pituitary tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2452–2462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Invitti, M. De Martin, L. Danesi, and F. Cavagnini, “Effect of injectable bromocriptine in patients with Cushing's disease,” Experimental and Clinical Endocrinology and Diabetes, vol. 103, no. 4, pp. 266–271, 1995. View at Google Scholar · View at Scopus
  33. S. W. J. Lamberts and J. C. Birkenhaeger, “Bromocriptine in Nelson's syndrome and Cushing's disease,” Lancet, vol. 2, no. 7989, p. 811, 1976. View at Google Scholar · View at Scopus
  34. S. W. J. Lamberts, J. G. M. Klijn, and M. De Quijada, “The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 51, no. 2, pp. 307–311, 1980. View at Google Scholar · View at Scopus
  35. R. Pivonello, M. C. De Martino, P. Cappabianca et al., “The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 223–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Godbout, M. Manavela, K. Danilowicz, H. Beauregard, O. D. Bruno, and A. Lacroix, “Cabergoline monotherapy in the long-term treatment of Cushing's disease,” European Journal of Endocrinology, vol. 163, no. 5, pp. 709–716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Vilar, L. A. Naves, M. F. Azevedo et al., “Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease,” Pituitary, vol. 13, no. 2, pp. 123–129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Pivonello, D. Ferone, W. W. De Herder et al., “Dopamine receptor expression and function in corticotroph ectopic tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 1, pp. 65–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. A. R. Lila, R. A. Gopal, S. V. Acharya et al., “Efficacy of cabergoline in uncured (persistent or recurrent) cushing disease after pituitary surgical treatment with or without radiotherapy,” Endocrine Practice, vol. 16, no. 6, pp. 968–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Cheung and A. Heaney, “Dopamine agonists and valvular heart disease,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 16, no. 4, pp. 316–320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. P. Heaney, M. Fernando, W. H. Yong, and S. Melmed, “Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas,” Nature Medicine, vol. 8, no. 11, pp. 1281–1287, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Elstner, E. A. Williamson, C. Zang et al., “Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells,” Breast Cancer Research and Treatment, vol. 74, no. 2, pp. 155–165, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Kubota, K. Koshizuka, E. A. Williamson et al., “Ligand for peroxisome proliferator-activated receptor γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo,” Cancer Research, vol. 58, no. 15, pp. 3344–3352, 1998. View at Google Scholar · View at Scopus
  44. B. Ambrosi, C. Dall'Asta, S. Cannavò et al., “Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease,” European Journal of Endocrinology, vol. 151, no. 2, pp. 173–178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. G. F. Pecori, C. Scaroni, E. Arvat et al., “Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease,” Clinical Endocrinology, vol. 64, no. 2, pp. 219–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. L. J. Hofland, J. van der Hoek, R. Feelders et al., “The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5,” European Journal of Endocrinology, vol. 152, no. 4, pp. 645–654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Boscaro, W. H. Ludlam, B. Atkinson et al., “Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 115–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Colao, S. Petersenn, J. Newell-Price et al., “A 12-month phase 3 study of pasireotide in cushing's disease,” New England Journal of Medicine, vol. 366, no. 10, pp. 914–924, 2012. View at Publisher · View at Google Scholar
  49. M. Losa, E. Mazza, M. R. Terreni et al., “Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases,” European Journal of Endocrinology, vol. 163, no. 6, pp. 843–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. D. H. George, B. W. Scheithauer, K. Kovacs et al., “Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma,” American Journal of Surgical Pathology, vol. 27, no. 10, pp. 1330–1336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. D. J. Holthouse, P. D. Robbins, R. Kahler, N. Knuckey, and P. Pullan, “Corticotroph pituitary carcinoma: case report and literature review,” Endocrine Pathology, vol. 12, no. 3, pp. 329–341, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Roncaroli, M. Faustini-Fustini, F. Mauri, S. Asioli, and G. Frank, “Crooke's hyalinization in silent corticotroph adenoma: report of two cases,” Endocrine Pathology, vol. 13, no. 3, pp. 245–249, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. G. A. Kaltsas, J. J. Mukherjee, P. N. Plowman, J. P. Monson, A. B. Grossman, and G. M. Besser, “The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 12, pp. 4233–4238, 1998. View at Google Scholar · View at Scopus
  54. G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman, “Clinical review: diagnosis and management of pituitary carcinomas,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 3089–3099, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. F. E. Kaiser, D. N. Orth, K. Mukai, and J. H. Oppenheimer, “A pituitary parasellar tumor with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides,” Journal of Clinical Endocrinology and Metabolism, vol. 57, no. 3, pp. 649–653, 1983. View at Google Scholar · View at Scopus
  56. S. Y. Park, Y. Rhee, J. C. Youn et al., “Ectopic Cushing's syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma,” Experimental and Clinical Endocrinology and Diabetes, vol. 115, no. 1, pp. 13–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. A. V. Schally, J. B. Engel, G. Emons, N. L. Block, and J. Pinski, “Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors,” Current Drug Delivery, vol. 8, no. 1, pp. 11–25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Kovacs, B. W. Scheithauer, M. Lombardero et al., “MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy,” Acta Neuropathologica, vol. 115, no. 2, pp. 261–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Raverot, N. Sturm, F. De Fraipont et al., “Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4592–4599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Curtò, M. L. Torre, F. Ferraù et al., “Temozolomide-induced shrinkage of a pituitary carcinoma causing cushing's disease - Report of a case and literature review,” TheScientificWorldJournal, vol. 10, pp. 2132–2138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. T. H. Dillard, S. H. Gultekin, J. B. Delashaw, C. G. Yedinak, E. A. Neuwelt, and M. Fleseriu, “Temozolomide for corticotroph pituitary adenomas refractory to standard therapy,” Pituitary, vol. 14, no. 1, pp. 80–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Páez-Pereda, D. Kovalovsky, U. Hopfner et al., “Retinoic acid prevents experimental Cushing syndrome,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1123–1131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. V. A. Castillo, M. F. Cabrera Blatter, N. V. Gómez, V. Sinatra, M. F. Gallelli, and M. C. Ghersevich, “Diurnal ACTH and plasma cortisol variations in healthy dogs and in those with pituitary-dependent Cushing's syndrome before and after treatment with retinoic acid,” Research in Veterinary Science, vol. 86, no. 2, pp. 223–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. J. C. Yao, M. H. Shah, T. Ito et al., “Everolimus for advanced pancreatic neuroendocrine tumors,” New England Journal of Medicine, vol. 364, no. 6, pp. 514–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Jouanneau, A. Wierinckx, F. Ducray et al., “New targeted therapies in pituitary carcinoma resistant to temozolomide,” Pituitary, vol. 15, no. 1, pp. 37–43, 2012. View at Publisher · View at Google Scholar
  66. F. E. Wondisford, “A new medical therapy for cushing disease?” Journal of Clinical Investigation, vol. 121, no. 12, pp. 4621–4623, 2011. View at Publisher · View at Google Scholar
  67. H. Fukuoka, O. Cooper, A. Ben-Shlomo et al., “EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas,” Journal of Clinical Investigation, vol. 121, no. 12, pp. 4712–4721, 2011. View at Publisher · View at Google Scholar
  68. R. A. Feelders, C. De Bruin, A. M. Pereira et al., “Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease,” New England Journal of Medicine, vol. 362, no. 19, pp. 1846–1848, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Gueorguiev and A. B. Grossman, “Pituitary tumors in 2010: a new therapeutic era for pituitary tumors,” Nature Reviews Endocrinology, vol. 7, no. 2, pp. 71–73, 2011. View at Publisher · View at Google Scholar · View at Scopus